November 28, 2016 - By Ruchi Gupta · 0 Comments
The stock of BELLUS HEALTH INCORPORATED (OTCMKTS:BLUSF) registered a decrease of 82.28% in short interest. BLUSF’s total short interest was 1,400 shares in November as published by FINRA. Its down 82.28% from 7,900 shares, reported previously. With 2,000 shares average volume, it will take short sellers 1 days to cover their BLUSF’s short positions. The stock closed at $0.175 during the last session. It is down 86.67% since April 25, 2016 and is downtrending. It has underperformed by 92.68% the S&P500.
BELLUS Health Inc. is a drug development firm focused on rare diseases. The company has a market cap of $11.01 million. The business activities of the Company are development of the Company’s core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. It currently has negative earnings. The Firm operates in the business segment of development of drugs for health solutions.
More notable recent BELLUS Health Inc (OTCMKTS:BLUSF) news were published by: Bloomberg.com which released: “Bellus Health Plummets After Protein-Fighting Drug Fails Test” on June 20, 2016, also Reuters.com with their article: “BRIEF-Bellus Health says Kiacta did not meet primary efficacy endpoint in …” published on June 20, 2016, Globenewswire.com published: “Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 …” on January 21, 2016. More interesting news about BELLUS Health Inc (OTCMKTS:BLUSF) were released by: Seekingalpha.com and their article: “BELLUS Health: Results From KIACTA Phase 3 Clinical Trial Expected In Mid-2016” published on November 18, 2015 as well as Businesswire.com‘s news article titled: “Auven Therapeutics and Bellus Health Announce Completion of Enrollment in the …” with publication date: May 27, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta